Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
ACAD Stock Chart & Stats
$22.81
-$0.09(-0.52%)
At close: 4:00 PM EST
$22.81
-$0.09(-0.52%)
Day’s Range― - ―
52-Week Range$13.40 - $28.35
Previous CloseN/A
Volume443.16K
Average Volume (3M)1.50M
Market Cap
$3.89B
Enterprise Value$3.03B
Total Cash (Recent Filing)$847.02M
Total Debt (Recent Filing)$54.81M
Price to Earnings (P/E)10.0
Beta1.09
Next Earnings
May 13, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.60
Shares Outstanding170,494,610
10 Day Avg. Volume1,903,757
30 Day Avg. Volume1,496,067
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)3.69
Price to Sales (P/S)4.22
P/FCF Ratio43.02
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue2.89
Enterprise Value/Gross Profit3.15
Enterprise Value/Ebitda25.81
Forecast
1Y Price Target
$32.43Price Target Upside42.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)0.48
Revenue Forecast (FY)$1.24B
Bulls Say, Bears Say
Bulls Say
Clinical PipelineAnalyst highlights mid-stage readouts for remlifanserin and ACP-204 as key catalysts that could materially re-rate the stock if results demonstrate efficacy and a favorable safety profile comparable to approved treatments.
Company GuidanceCompany guidance above analyst consensus signals management confidence in Nuplazid demand and supports expectations for meaningful revenue growth.
Valuation UpsideAnalyst views the company as undervalued given strong execution of approved products and an underappreciated development pipeline, indicating potential upside as clinical programs progress.
Bears Say
EU Regulatory SetbackA formal CHMP refusal of marketing authorization for Daybue on efficacy grounds creates a regulatory overhang that could delay European commercialization and limit near-term international revenue.
Rebate-related Reporting HeadwindsA one-time rebate and accrual adjustment reduced reported Nuplazid sales under accounting rules, introducing volatility and obscuring underlying volume growth.
Rising Operating ExpensesProjected increases in selling, general and administrative expenses and research and development spending raise near-term cost pressure and could weigh on profitability expectations.
ACADIA Pharmaceuticals News
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $13.40 and its highest was $28.35 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is $3.89B.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is May 13, 2026 which is in 70 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Feb 25, 2026. The company reported $1.6 earnings per share for the quarter, beating the consensus estimate of $0.137 by $1.463.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is 0.06.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 170,494,610 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $1.6 in its last earnings report, beating expectations of $0.137. Following the earnings report the stock price went down -1.322%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Currently, no hedge funds are holding shares in ACAD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ACADIA Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.43 (42.17% Upside)
$32.43 (42.17% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 149.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Bullish
Bullish news 78%
Bearish news 22%
Bearish news 22%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.37%
12-Months-Change
Fundamentals
Return on Equity
39.89%
Trailing 12-Months
Asset Growth
31.69%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACAD Company Deck
ACAD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and clear growth drivers: record adjusted revenue (> $1 billion), double-digit growth for both NUPLAZID and DAYBUE, an approved new DAYBUE formulation (STIX) with early traction, meaningful pipeline catalysts (remlifanserin Phase II readout in Aug–Oct 2026 and multiple planned study initiations), and a solid cash position. Offsetting these positives were industry- and company-specific risks: a negative CHMP trend vote for trofinetide in the EU creating regulatory uncertainty, a nonrecurring $20M IRA-related net sales adjustment plus cash outflows from IRA invoices, and a notable step-up in SG&A that will pressure near-term margins. On balance, the highlights — notably strong top-line growth, product launches, pipeline catalysts, and healthy cash — outweigh the lowlights, which are largely regulatory and timing risks.View all ACAD earnings summariesACAD Stock 12 Month Forecast
Average Price Target
$32.43
▲(42.17% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
PTC Therapeutics
―
Krystal Biotech
―
MoonLake Immunotherapeutics
―
Arcellx Inc
―
Ownership Overview
Currently, No data available
---